



PERMANENT ADMINISTRATIVE ORDER

BP 96-2020
CHAPTER 855
BOARD OF PHARMACY

FILED
12/23/2020 3:07 PM
ARCHIVES DIVISION
SECRETARY OF STATE
& LEGISLATIVE COUNSEL

FILING CAPTION: Protocol Compendia updated to incorporate recent Public Health and Pharmacy Formulary Advisory Committee (PHPFAC) recommendations.

EFFECTIVE DATE: 12/23/2020

AGENCY APPROVED DATE: 12/17/2020

CONTACT: Rachel Melvin
971-673-0001
pharmacy.rulemaking@oregon.gov

800 NE Oregon St., Suite 150
Portland, OR 97232

Filed By:
Rachel Melvin
Rules Coordinator

AMEND: 855-020-0300

RULE TITLE: Protocol Compendium

NOTICE FILED DATE: 10/22/2020

RULE SUMMARY: Adds one new patient care protocol to the compendia.

RULE TEXT:

A pharmacist may prescribe, via statewide drug therapy management protocol and according to regulations outlined in this Division, an FDA-approved drug and device listed in the following compendium:

(1) Continuation of therapy

(a) A pharmacist may prescribe any non-controlled medication to extend a patient's prescription therapy to avoid interruption of treatment; and

(b) In such cases, a pharmacist shall only prescribe a drug quantity sufficient for the circumstances, not to exceed a 60-day supply, and no more than two extensions in a 12-month period per medication.

(2) Conditions

(a) Cough and cold symptom management

(A) Pseudoephedrine products for patients 18 years of age and older, verified by positive identification, not to exceed 3.6 grams or a 60-count quantity per prescription, whichever is less, or a total of three prescriptions in a 12-month period. Pharmacist must review PDMP prior to issuing prescription and retain documentation of PDMP review;

(B) Benzonatate, for the treatment of cough, not to exceed a 7-day supply;

(C) Short-acting beta agonists, not to exceed 1 inhaler with or without a spacer, or 1 box of nebulizer ampules, per year;

(D) Intranasal corticosteroids.

(b) Vulvovaginal candidiasis (VVC) Protocol (v. August 2020)

(3) Preventative care

(a) Emergency Contraception, not including abortifacients.

(b) Male and female condoms.

(c) Tobacco Cessation, NRT (Nicotine Replacement Therapy) and Non-NRT Protocol (v. August 2020). A pharmacist is permitted to provide patient care services pursuant to this protocol only upon documented completion of a minimum of

2 hours of tobacco cessation continuing education.

(d) Travel Medications Protocol (v. August 2020). A pharmacist who meets criteria to immunize pursuant to OAR 855-019-0270 is permitted to provide patient care services pursuant to this protocol only upon documented completion of: minimum of 4 hour certificate for pharmacy-based travel medicine services intended for the pharmacist (one-time requirement), and minimum of 1 hour of travel medication continuing education every 24 months.

(e) HIV Post-exposure Prophylaxis (PEP) Protocol (v. August 2020). A pharmacist is permitted provide patient care services pursuant to this protocol only upon documented completion of a comprehensive training program for the prescribing and dispensing of HIV prevention medications, to include related trauma-informed care.

(f) HIV Pre-exposure Prophylaxis (PrEP) Protocol (v. December 2020). A pharmacist is permitted provide patient care services pursuant to this protocol only upon documented completion of a comprehensive training program for the prescribing and dispensing of HIV prevention medications, to include related trauma-informed care.

[Publications referenced are available from the agency.]

STATUTORY/OTHER AUTHORITY: ORS 689.205

STATUTES/OTHER IMPLEMENTED: ORS 689.645, ORS 689.649